We previously demonstrated that MC3324 is a dual LSD1 and UTX inhibitor that negatively regulates ERα signaling and promotes activation of programmed cell death pathways in BC both sensitive and resistant to endocrine therapies [21]. Here, KDM1A is linked to breast cancer.